STOCK TITAN

AGENUS INC (AGEN) awards 100,000 stock options to its CMO

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AGENUS INC reported that Chief Medical Officer Steven J. O'Day received a grant of 100,000 stock options on 2026-08-05. The options have an exercise price of $7.7800 per share, expire on 2036-08-05, and were awarded under the 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments thereafter.

Positive

  • None.

Negative

  • None.
Insider O'Day Steven J
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option F1 100,000 $0.00 $0.00
Holdings After Transaction: Stock Option — 100,000 shares (Direct)
Footnotes (1)
  1. F1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.
Stock options granted 100,000 options Grant to Chief Medical Officer on 2026-08-05
Exercise price $7.7800 per share Conversion or exercise price of stock option grant
Expiration date 2036-08-05 Stock option grant expires on this date
Vesting period 3 years Options vest over three years from the grant date
Underlying common shares 100,000 shares Underlying Agenus common stock covered by the options
Stock Option financial
"Security title reported as Stock Option for the grant"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Equity Incentive Plan financial
"Option awarded under the 2019 Amended and Restated Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vesting financial
"Options vest over three years, with one-third vesting after one year"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Grant Date financial
"One-third vesting on the first anniversary of the Grant Date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Agenus (AGEN) report for Steven J. O'Day?

Agenus reported that Chief Medical Officer Steven J. O'Day received a grant of 100,000 stock options on 2026-08-05. The options were issued as a compensation award under the company’s 2019 Amended and Restated Equity Incentive Plan.

How many stock options were granted to the Agenus (AGEN) CMO and at what exercise price?

Steven J. O'Day was granted 100,000 stock options with an exercise price of $7.7800 per share. These options give him the right to purchase Agenus common stock at that price if and when they are exercised.

When do Steven J. O'Day’s Agenus (AGEN) stock options expire?

The granted stock options expire on 2036-08-05. After this expiration date, any unexercised options from this 100,000-unit grant will no longer be exercisable for Agenus common stock.

What is the vesting schedule for the Agenus (AGEN) stock options granted to the CMO?

The options vest over three years: one-third vests on the first anniversary of the grant date, and the remaining two-thirds vest in two equal annual installments thereafter, subject to the terms of the equity incentive plan.

Does this Agenus (AGEN) Form 4 show any stock sales by the CMO?

No stock sales are reported; the Form 4 shows only a grant of 100,000 stock options to Steven J. O'Day. The transaction is categorized as a grant, award, or other acquisition of derivative securities.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Day Steven J

(Last)(First)(Middle)
C/O AGENUS INC.
3 FORBES ROAD

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$7.7808/05/2026A100,000 (1)08/05/2036Common Stock100,000$0.00100,000D
Explanation of Responses:
1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.
/s/ Melissa Orilall, as Attorney-in-Fact for Steven O'Day08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)